INDIANAPOLIS, Ind. – Nearly 200 Eli Lilly employees will lose their jobs as the Indianapolis-based company reduces its research and development workforce.
Eli Lilly says the cuts will help the company refocus efforts on certain key research areas like molecule-making capabilities, Alzheimer’s disease and immunology.
On Friday, many employees were offered what the company is calling a “voluntary exit program.” Those workers have until later this month to decide.
The reductions, which represent less than 3 percent of Lilly’s global R&D workforce, are not related to the recent failure of the company’s Alzheimer’s drug Solanezumab.
It’s not clear if the job cuts will come solely from Indianapolis.